$VNDA

AI 分析

生成於 May 12, 2026

AI Score
55/ 100
Hold$VNDA

Vanda Pharmaceuticals Inc.

$VNDANASDAQHealthcareSmall-Cap

Vanda Pharmaceuticals develops and commercializes therapies for central nervous system disorders. Key products include Hetlioz for non-24-hour sleep-wake disorder and Fanapt for schizophrenia.

Market Cap
$350.0M
Revenue (TTM)
$250.0M
-5.0%
Net Income (TTM)
$25.0M
-15.0%
EPS (TTM)
$0.45
P/E Ratio
14.0
Dividend Yield
0.0%
52-Week Range
$4.50-$8.00
Beta
0.65
Dimension Scores
Fundamental
58
Technical
48
Sentiment
52
Risk / Reward
60
Momentum
45
FundTechSentRiskMome
Financial Health
Profitability
63moderate
Growth
48weak
Liquidity
68strong
Solvency
60moderate
Efficiency
56moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $VNDA

Free · No credit card required

免責聲明: AI 生成的分析僅供教育參考,不構成投資建議。請始終諮詢合格的理財顧問。

探索更多

用 AI 分析任意股票

獲取涵蓋基本面、技術面、情緒面、風險評估和投資論點的結構化研究報告——約 60 秒完成。